

IASLC publishes lurbinectedin (PharmaMar) abstracts titles for small cell lung cancer

Madrid, August 12th, 2019. - PharmaMar (MSE:PHM) announces that the International Association for the Study of Lung Cancer (IASLC) has published the list of abstracts titles to be presented during the congress that will take place from September 7th to 10th in Barcelona. Three abstracts will be presented on lurbinectedin for the treatment of small cell lung cancer.

- **Targeting Transcription (Including Lurbinectedin)**
Mini Symposium Oral Session: "Molecular Subsets and Novel Targeted Approaches to Small Cell and Neuroendocrine Cancers," on September 10th, 2019, from 12:00 to 12:15 in the Colorado Springs Room
Presenter: Dr. Camilla L. Christensen, Harvard University
- **Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥ 30 Days After Last Platinum Dose.**
(Abstract 1710).
Poster: September 8th, 2019, from 8:00 to 18:00 in the Exhibit Hall
Session: P1.12 - Small Cell Lung Cancer/NET
Lead author: José Manuel Trigo, Hospital Universitario Virgen de la Victoria.
- **Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Ib Trials.** (Abstract 1588).
Poster: September 9th, 2019, from 8:00 to 18:00 in the Exhibit Hall
Session: P2.12 - Small Cell Lung Cancer/NET
Lead author: Santiago Ponce, Hospital Universitario 12 de Octubre.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals

with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About lurbinectedin

Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Phone: +34 918466000

Investor Relations:

José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com